Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cendakimab - Celgene Corporation

Next Previous
Drug Profile

Cendakimab - Celgene Corporation

Alternative Names: ABT-308; BMS-986355; CC 93538; RPC 4046

Latest Information Update: 22 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie; Celgene Corporation
  • Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eosinophilic oesophagitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Eosinophilic gastroenteritis; Eosinophilic oesophagitis
  • Phase II Atopic dermatitis; Systemic lupus erythematosus
  • Discontinued Asthma

Most Recent Events

  • 22 May 2025 Pooled pharmacokinetics and adverse events data from two phase I trials presented at the 32nd United European Gastroenterology Week (UEG-2024)
  • 11 Oct 2024 Celgene completes a phase I trial in Eosinophilic oesophagitis (Treatment-experienced) in USA (Parenteral) (NCT05175352)
  • 29 Aug 2024 Celgene completes a phase III trial in Eosinophilic oesophagitis (In adolescents, In children, In the elderly, In adults) in US, Germany, Argentina, Australia Italy Japan, Poland, Portugal, Austria, Belgium, Canada, Israel, Spain and United Kingdom and Switzerland (SC, Injection) (NCT04753697)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top